{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Intravenous+Infection",
    "query": {
      "condition": "Intravenous Infection"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 344,
    "total_pages": 35,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Intravenous+Infection&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T20:51:37.728Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00880789",
      "title": "Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and Adenovirus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cytomegalovirus Infection",
        "Adenovirus Infection"
      ],
      "interventions": [
        {
          "name": "CMV/AdV specific T cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "Up to 90 Years"
      },
      "enrollment_count": 9,
      "start_date": "2009-05",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2014-10-15",
      "last_synced_at": "2026-07-22T20:51:37.728Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00880789"
    },
    {
      "nct_id": "NCT03667690",
      "title": "Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Candidemia",
        "Mycoses",
        "Fungal Infection",
        "Invasive Candidiases"
      ],
      "interventions": [
        {
          "name": "Rezafungin for Injection",
          "type": "DRUG"
        },
        {
          "name": "Caspofungin",
          "type": "DRUG"
        },
        {
          "name": "Fluconazole",
          "type": "DRUG"
        },
        {
          "name": "intravenous placebo",
          "type": "DRUG"
        },
        {
          "name": "oral placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 199,
      "start_date": "2018-10-07",
      "completion_date": "2021-10-07",
      "has_results": true,
      "last_update_posted_date": "2023-01-06",
      "last_synced_at": "2026-07-22T20:51:37.728Z",
      "location_count": 19,
      "location_summary": "Birmingham, Alabama • Sacramento, California • Atlanta, Georgia + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03667690"
    },
    {
      "nct_id": "NCT03800173",
      "title": "A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Marburg Virus Disease"
      ],
      "interventions": [
        {
          "name": "galidesivir",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioCryst Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 32,
      "start_date": "2018-12-10",
      "completion_date": "2019-04-30",
      "has_results": true,
      "last_update_posted_date": "2021-07-23",
      "last_synced_at": "2026-07-22T20:51:37.728Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03800173"
    },
    {
      "nct_id": "NCT00292942",
      "title": "Study of the Safety of Intravenous Artesunate",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malaria",
        "Malaria, Cerebral"
      ],
      "interventions": [
        {
          "name": "Intravenous Artesunate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 26,
      "start_date": "2006-06-12",
      "completion_date": "2008-01",
      "has_results": true,
      "last_update_posted_date": "2018-10-25",
      "last_synced_at": "2026-07-22T20:51:37.728Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00292942"
    },
    {
      "nct_id": "NCT00473824",
      "title": "Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sequelae of Viral Hepatitis",
        "Transplantation Infection",
        "Evidence of Liver Transplantation"
      ],
      "interventions": [
        {
          "name": "Hepatitis C Immune Globulin Intravenous (Human) 5%",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ADMA Biologics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 7,
      "start_date": "2007-05",
      "completion_date": "2009-02",
      "has_results": true,
      "last_update_posted_date": "2021-07-30",
      "last_synced_at": "2026-07-22T20:51:37.728Z",
      "location_count": 3,
      "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00473824"
    },
    {
      "nct_id": "NCT00001017",
      "title": "Comparison of Fluconazole and Amphotericin B in the Treatment of Brain Infections in Patients With AIDS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Meningitis, Cryptococcal",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Fluconazole",
          "type": "DRUG"
        },
        {
          "name": "Amphotericin B",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 330,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2011-03-14",
      "last_synced_at": "2026-07-22T20:51:37.728Z",
      "location_count": 28,
      "location_summary": "Los Angeles, California • Miami, Florida • Indianapolis, Indiana + 15 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001017"
    },
    {
      "nct_id": "NCT00921024",
      "title": "Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract Infections",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Complicated Urinary Tract Infection"
      ],
      "interventions": [
        {
          "name": "CXA-101",
          "type": "DRUG"
        },
        {
          "name": "Ceftazidime",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 129,
      "start_date": "2009-06-30",
      "completion_date": "2010-03-11",
      "has_results": true,
      "last_update_posted_date": "2018-10-18",
      "last_synced_at": "2026-07-22T20:51:37.728Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Orlando, Florida • Decatur, Georgia + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Picayune",
          "state": "Mississippi"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00921024"
    },
    {
      "nct_id": "NCT02734862",
      "title": "CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Candidemia",
        "Mycoses",
        "Fungal Infection",
        "Fungemia",
        "Invasive Candidiasis"
      ],
      "interventions": [
        {
          "name": "CD101",
          "type": "DRUG"
        },
        {
          "name": "Caspofungin",
          "type": "DRUG"
        },
        {
          "name": "Fluconazole",
          "type": "DRUG"
        },
        {
          "name": "intravenous placebo",
          "type": "DRUG"
        },
        {
          "name": "oral placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 207,
      "start_date": "2016-07-26",
      "completion_date": "2019-07",
      "has_results": true,
      "last_update_posted_date": "2020-12-08",
      "last_synced_at": "2026-07-22T20:51:37.728Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • Davis, California • Miami, Florida + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Davis",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02734862"
    },
    {
      "nct_id": "NCT04778059",
      "title": "Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "2019 Novel Coronavirus Infection",
        "COVID-19 Virus Infection",
        "SARS Coronavirus 2 Infection",
        "SARS-CoV-2 Infection",
        "Respiratory Distress Syndrome, Adult",
        "Adult Respiratory Distress Syndrome"
      ],
      "interventions": [
        {
          "name": "USB002",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "US Biotest, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2021-07-27",
      "completion_date": "2022-05-10",
      "has_results": true,
      "last_update_posted_date": "2023-12-01",
      "last_synced_at": "2026-07-22T20:51:37.728Z",
      "location_count": 1,
      "location_summary": "Tucson, Arizona",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04778059"
    },
    {
      "nct_id": "NCT05204368",
      "title": "Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Complicated Urinary Tract Infection Including Acute Pyelonephritis"
      ],
      "interventions": [
        {
          "name": "Combination of Imipenem/Cilastatin and XNW4107",
          "type": "DRUG"
        },
        {
          "name": "Meropenem",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Evopoint Biosciences Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 780,
      "start_date": "2023-03-30",
      "completion_date": "2025-12",
      "has_results": false,
      "last_update_posted_date": "2023-02-16",
      "last_synced_at": "2026-07-22T20:51:37.728Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05204368"
    }
  ]
}